JP2022534704A - オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 - Google Patents

オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 Download PDF

Info

Publication number
JP2022534704A
JP2022534704A JP2021569903A JP2021569903A JP2022534704A JP 2022534704 A JP2022534704 A JP 2022534704A JP 2021569903 A JP2021569903 A JP 2021569903A JP 2021569903 A JP2021569903 A JP 2021569903A JP 2022534704 A JP2022534704 A JP 2022534704A
Authority
JP
Japan
Prior art keywords
group
alkyl
halogen
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534704A5 (https=
JPWO2020247445A5 (https=
Inventor
メコネン，ブリュー
パテル，へマントバイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hager Biosciences LLC
Original Assignee
Hager Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hager Biosciences LLC filed Critical Hager Biosciences LLC
Publication of JP2022534704A publication Critical patent/JP2022534704A/ja
Publication of JP2022534704A5 publication Critical patent/JP2022534704A5/ja
Publication of JPWO2020247445A5 publication Critical patent/JPWO2020247445A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021569903A 2019-06-04 2020-06-03 オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 Pending JP2022534704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856830P 2019-06-04 2019-06-04
US62/856,830 2019-06-04
PCT/US2020/035848 WO2020247445A1 (en) 2019-06-04 2020-06-03 Imidazolo derivatives, compositions and methods as orexin antagonists

Publications (3)

Publication Number Publication Date
JP2022534704A true JP2022534704A (ja) 2022-08-03
JP2022534704A5 JP2022534704A5 (https=) 2023-06-08
JPWO2020247445A5 JPWO2020247445A5 (https=) 2023-06-08

Family

ID=73652477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569903A Pending JP2022534704A (ja) 2019-06-04 2020-06-03 オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法

Country Status (9)

Country Link
US (2) US12187737B2 (https=)
EP (1) EP3972588A4 (https=)
JP (1) JP2022534704A (https=)
KR (1) KR20220016918A (https=)
CN (1) CN114286675A (https=)
AU (1) AU2020286381C1 (https=)
CA (1) CA3140170A1 (https=)
SG (1) SG11202112827QA (https=)
WO (1) WO2020247445A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114286675A (zh) 2019-06-04 2022-04-05 海格生物科学有限责任公司 作为食欲肽拮抗剂的咪唑衍生物、组合物以及方法
US20220315602A1 (en) * 2019-06-04 2022-10-06 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
AU2020407664A1 (en) 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
WO2025101004A1 (ko) * 2023-11-08 2025-05-15 한양대학교 에리카산학협력단 6-aryl imidazo[2,1-b]thi/oxazole-2-carboxilic acid 유도체 및 이를 유효성분으로 함유하는 알츠하이머병 치료용 약학 조성물
WO2025188753A1 (en) * 2024-03-05 2025-09-12 Hager Biosciences, Llc Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02237988A (ja) 1988-11-18 1990-09-20 Nissan Chem Ind Ltd イソオキサゾロピリジン系メバロノラクトン類
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
JP3810097B2 (ja) 1993-01-15 2006-08-16 明治製菓株式会社 ピロリジン−２−イルカルボニル複素環式化合物誘導体
ES2196806T3 (es) 1998-05-08 2003-12-16 Smithkline Beecham Plc Derivados de fenilurea y de feniltiourea.
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
JP4246490B2 (ja) 2000-11-28 2009-04-02 スミスクライン ビーチャム ピー エル シー オレキシン受容体のアンタゴニストとしてのモルホリン誘導体
IL158463A0 (en) 2001-05-05 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amines
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
US20060040937A1 (en) 2002-09-18 2006-02-23 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
UA85937C2 (uk) 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Макроліди
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2006127550A1 (en) 2005-05-23 2006-11-30 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
UA106873C2 (uk) * 2006-12-01 2014-10-27 Мерк Шарп Енд Доме Корп. Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP4881476B2 (ja) 2007-05-23 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション ピリジルピペリジン・オレキシン受容体アンタゴニスト
ATE524466T1 (de) 2007-07-03 2011-09-15 Actelion Pharmaceuticals Ltd 3-azabicycloä3.3.0üoktanverbindungen
CA2695742C (en) 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
FR2925907B1 (fr) 2008-01-02 2010-10-15 Sanofi Aventis DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2252587B1 (en) 2008-02-12 2011-07-20 F. Hoffmann-La Roche AG Piperidine sulfonamide derivatives
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009307913A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2349269A4 (en) 2008-10-21 2012-04-25 Merck Sharp & Dohme 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
WO2010141275A1 (en) 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide orexin receptor antagonists
US20120101106A1 (en) 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
WO2011100614A1 (en) 2010-02-11 2011-08-18 Vanderbilt University BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
UA109457C2 (ru) * 2010-10-21 2015-08-25 Байєр Інтелекчуал Проперті Гмбх 1-(гетероциклический карбонил)-2-замещенные пирролидины
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
KR101873083B1 (ko) * 2011-02-18 2018-06-29 이도르시아 파마슈티컬스 리미티드 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체
EP2730573A4 (en) 2011-07-05 2014-12-03 Taisho Pharmaceutical Co Ltd METHYLPIPERIDINDERIVAT
WO2013062858A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10081624B2 (en) * 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN114286675A (zh) 2019-06-04 2022-04-05 海格生物科学有限责任公司 作为食欲肽拮抗剂的咪唑衍生物、组合物以及方法
US20220315602A1 (en) 2019-06-04 2022-10-06 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists

Also Published As

Publication number Publication date
AU2020286381B2 (en) 2025-04-03
US20240409554A1 (en) 2024-12-12
CN114286675A (zh) 2022-04-05
EP3972588A1 (en) 2022-03-30
CA3140170A1 (en) 2020-12-10
AU2020286381A1 (en) 2022-01-20
AU2020286381C1 (en) 2025-07-10
US12187738B2 (en) 2025-01-07
SG11202112827QA (en) 2021-12-30
KR20220016918A (ko) 2022-02-10
US20220259224A1 (en) 2022-08-18
US12187737B2 (en) 2025-01-07
WO2020247445A1 (en) 2020-12-10
EP3972588A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
US12187738B2 (en) Imidazolo derivatives, compositions and methods as orexin antagonists
US12275744B2 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
TW202039471A (zh) Apol1抑制劑及其使用方法
CA3129067A1 (en) Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
TW201823208A (zh) N－醯基胺基酸化合物及其使用方法
CA3018346A1 (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EP4423068B1 (en) Rxfp1 agonists
TW202333674A (zh) 作為ｇｌｐ－１受體調節劑之某些２，５－二氮雜雙環〔４．２．０〕辛烷
US20250268903A1 (en) Rxfp1 agonists
EP3481801B1 (en) Indoline derivatives and method for using and producing the same
JP2024546943A (ja) Ｒｘｆｐ１アゴニストとしてのテトラリン、フェニルシクロブタン、およびフェニルシクロペンタン類似体
CN120187425A (zh) 作为食欲素受体拮抗剂的取代的吡唑和咪唑组合物、治疗神经和精神疾患的方法
WO2022249006A1 (en) Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists
WO2025188753A1 (en) Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
NZ786241A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250507